Hims & Hers (HIMS) is trading down over 4% to $25.79, underperforming a broadly stronger technology market. The decline occurs on the same day the company announced a significant new product initiative.
- The company today launched "Labs AI", an AI-powered care agent designed to provide customers with clearer, personalized insights from their lab results.
- Labs AI analyzes a user's biomarker history and health profile to help them understand their health and potential actions, while clinicians will still provide official diagnoses and medical advice.
- The stock's negative reaction suggests that investors may be unimpressed with the announcement or are focused on other factors, such as upcoming earnings on May 11 or recent analyst price target reductions.